Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation.
LEO Pharma, a leader in medical dermatology, announces the appointment of Sophie Lamle, D.Phil, as new Executive Vice President (EVP) of Development. Sophie will join the Global Leadership Team and will play an instrumental role in further strengthening LEO Pharma’sSearch & Development model.
Health Technology Insights: Corvus Launches to Streamline Surgical Referrals and Access to Care
Sophie joins LEO Pharma from Teva Pharmaceuticals where she led the global R&D innovative medicines team, overseeing assets across Immunology and Neuroscience, from discovery through commercialization. She has more than 20 years of experience in the pharmaceutical industry driving innovation, clinical development and strategic transformation.
“I’m very much looking forward to becoming part of the LEO Pharma team, bringing purposeful innovation in medical dermatology. I’m passionate about making a fundamental difference for all those suffering from skin disease. The Search & Development model resonates strongly with me, as I am driven by forging strategic partnerships that accelerate asset progression and demonstrate value through differentiated clinical programs. I look forward to contributing to the next wave of growth at LEO Pharma,” says, Sophie Lamle.
Health Technology Insights: INOVIO Seeks Accelerated Approval for INO-3107 in RRP
Sophie is originally from the United Kingdom and has a D.Phil. in Chemistry from the University of Oxford. Prior to her role at Teva, Sophie brings experience spanning a variety of roles in Vectura, Novartis Pharmaceuticals and IQVIA.
“Sophie is a very strong international profile and passionate about making a fundamental difference through innovation. With her experience and knowhow in partnerships and co-creation, as well as her strong leadership skills, she is the ideal candidate to lead Development in the next chapter of our journey,” says CEO, Christophe Bourdon.
Sophie Lamle will join LEO Pharma as EVP of Development on December 1, 2025. Prior to her start, Mark Levick will conclude his tenure as interim EVP but will continue serving as a member of the Board of Directors and Chair of the Innovation Committee.
Health Technology Insights: GeneSight Study Links Faster Relief to Test-Guided Care
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
